Peroxisome proliferator-activated receptor ligands as antiatherogenic agents: Panacea or another Pandora's box?

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 7, Issue 1, 2002, Pages 1-8

  Molavi, Behzad ^a   Rasouli, Neda ^a   Mehta, Jawahar L ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Atherosclerosis; Inflammation; Peroxisome proliferator activated receptors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BEZAFIBRATE; CELL NUCLEUS RECEPTOR; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEUKOTRIENE B4; LIPOPROTEIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PIRINIXIC ACID; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD CLOTTING; CELL GROWTH; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FIBRINOLYSIS; GENE EXPRESSION REGULATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIPOPROTEIN METABOLISM; MACROPHAGE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RECEPTOR INTRINSIC ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOOTH MUSCLE FIBER; THROMBOCYTE AGGREGATION; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE;

EID: 0036117991     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840200700i101     Document Type: Review

References (66)

1. Biomechanical strain induces class a scavenger receptor expression in human monocyte/macrophages and THP-1 cells: A potential mechanism of increased atherosclerosis in hypertension
2. Endothelium in insulin resistance and diabetes
3. Cellular and molecular studies of atherogenesis
4. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice
5. The lipid-laden foam cell: An elusive target for therapeutic intervention
6. The pathogenesis of atherosclerosis: A perspective for the 1990s
7. Identification and autoregulation of receptor for ox-LDL in cultured human coronary artery endothelial cells
8. Biosynthesis and post-translational processing of lectin-like oxidized low density lipoprotein receptor-1 (LOX-1). N-linked glycosylation affects cell-surface expression and ligand binding
9. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species
10. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: Evidence from use of antisense LOX-1 mRNA and chemical inhibitors
11. Lowering LDL cholesterol: Questions from recent meta-analyses and subset analyses of clinical trial data issues from the interdisciplinary council on reducing the risk for coronary heart disease, Ninth Council meeting
12. Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47)
13. Aspirin therapy in diabetes
14. The genesis of atherosclerosis and risk factors: A review
15. Peroxisome proliferator-activated receptors in the cardiovascular system
16. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor
17. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene
18. The peroxisome in retrospect
19. The PPARs: From orphan receptors to drug discovery
20. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?
21. The nuclear receptor superfamily: The second decade
22. Expression and function of PPAR-gamma in rat and human vascular smooth muscle cells
23. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction
24. PPAR-γ ligands inhibit TNF-alpha-induced LOX-1 expression in cultured endothelial cells
25. Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator-activated receptor-γ
26. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway
27. PPAR-gamma ligands inhibit TNF-alpha-induced LOX-1 expression in cultured endothelial cells
28. Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells
29. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells
30. The peroxisome proliferator-activated receptor (PPAR-gamma) as a regulator of monocyte/macrophage function
31. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators
32. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
33. Current views on the mechanism of action of thiazolidinedione insulin sensitizers
34. Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats
35. Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization
36. Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy
37. Troglitazone inhibits atherosclerotic lesion formation and macrophage accumulation in male LDLR-/- mice fed high fat and high fructose diets
38. Response of experimental retinal neovascularization to thiazolidinediones
39. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs
40. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: A serial intravascular ultrasound study
41. Peroxisome proliferator-activated receptor gamma ligands and atherosclerosis: Ending the heartache
42. Glitazones and the potential improvement of lipid profiles in diabetes patients at high risk for cardiovascular disease
43. A prospective, randomized comparison of the metabolic effects of pioglitazone vs rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone
44. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly
45. Myocardial infarction in young patients
46. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome
47. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus
48. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups
49. Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism
50. Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells
51. Conclusions from the VA-HIT study
52. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT)
53. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease
54. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis
55. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging
56. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis
57. Activation of human aortic smooth-muscle cells is inhibited by PPAR alpha but not by PPAR gamma activators
58. Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta
59. Peroxisome proliferator-activated receptors in atherosclerosis and inflammation - An update
60. Physiological and pharmacological function of PPARs
61. Up-regulation of uncoupling protein 3 gene expression by fatty acids and agonists for PPARs in L6 myotubes
62. Uncoupling proteins: Functional characteristics and role in the pathogenesis of obesity and type II diabetes
63. Overexpression of UCP3 in cultured human muscle lowers mitochondrial membrane potential, raises ATP/ADP ratio, and favors fatty acid vs. glucose oxidation
64. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer
65. A nuclear receptor to prevent colon cancer
66. PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture